Exogenous expression of DNAJB8 can enhance the tumorigenicity of CRC cells with increasing levels of stem cell markers, indicating that DNAJB8 is a promising therapeutic target for immunotherapy against CSCs and CICs in CRC patients [90]. This evidence concerns the gene DNAJB8 and colorectal carcinoma.